MCT3 can be explored as a molecular target in a subtype of breast cancers [38] and MCT4 is increased in glycolytic tissues and several cancers including hepatocellular carcinoma [39] and can predict patient outcomes. Here, SLC16A8 is linked to hepatocellular carcinoma.